Robert Francomano: Significant change in regulatory priorities by the FDA
Robert Francomano, Chief Commercial Officer at SELLAS, shared on LinkedIn:
“The recent emphasis by the FDA on considering overall survival (OS) over progression-free survival (PFS) when evaluating cancer drug approvals marks a significant change in regulatory priorities.
It showcases the agency’s dedication to ensuring that medications deliver advantages. This adjustment presents both challenges and opportunities for smaller biotech firms that are under growing pressure to prove the benefits of OS.
It highlights the balance between fostering innovation and providing solid evidence of positive long-term outcomes for patients. This article from BioSpace explores how this shift impacts the development, approval process, and market dynamics of cancer therapies.”
Procced to the article.
Source: Robert Francomano/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023